This site is intended only for healthcare professionals resident in India
Menu
Close
Menu
Close
Almost half of all cases of invasive aspergillosis and a high proportion of mucormycosis cases are diagnosed or treated in the ICU1,2
Whilst diagnostics and treatment have progressed, invasive fungal infections continue to pose a serious threat and are associated with extremely high mortality.3–6
Invasive aspergillosis and mucormycosis typically affect individuals who are immunocompromised and/or have established risk factors,2,7–10 but cases are also being reported in critically ill patients admitted to the ICU.7,8,10 Establishing a diagnosis in this setting can be challenging as the classic diagnostic definitions (EORTC/MSGERC) for invasive fungal disease were created primarily for patients with cancer and stem cell or solid organ transplant,7,11 and the ICU patient population may present with different features.11–13
Lorem ipsum dolor sit amet, consectetur badipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Adapted from reference 7.
An emerging association between COVID-19 and pulmonary aspergillosis/mucormycosis14–18
The global pandemic has shown that invasive mould infections such as aspergillosis and mucormycosis can represent an additional threat to COVID-19 patients who are admitted to the ICU or develop ARDS:14–18 cases of COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) are increasingly being reported.19 Clinical and radiological signs of CAPA and CAM can overlap – and there have been reports of simultaneous mixed superinfection.18–20
a. Cases of invasive aspergillosis (mainly pulmonary) reported among ICU patients in different prospective and retrospective studies.
Adapted from references 12, 21-26.
How can CRESEMBA® help your patients?
In the complicated clinical scenario ICU patients often find themselves in, think CRESEMBA®:
CRESEMBA® can offer the flexibility you need, so that you can focus on your patient’s underlying condition.3,4,27,28
ARDS, acute respiratory distress syndrome; BMT, bone marrow transplant; CAM, COVID-19-associated mucormycosis; CAPA, COVID-19-associated pulmonary aspergillosis; COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; EORTC/MSGERC, European Organization for Research and Treatment of Cancer/Mycoses Study Group Education and Research Consortium; ESRD, end-stage renal disease; HIV, human immunodeficiency virus; ICU, intensive care unit; PK, pharmacokinetic.
Prescribing Information:
CRESEMBA® (isavuconazole)
References:
PP-CRB-IND-0472 July 2022
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.